Andersons pediatric cardiology 1581

SE,SchuetzTJ,KimuraA.AphaseI/IIclinical
trialofenzymereplacementtherapyin
mucopolysaccharidosisII(huntersyndrome).
MolGenetMetab.2007;90(3):329–337.
46.MuenzerJ,WraithJE,BeckM,etal.Aphase
II/IIIclinicalstudyofenzymereplacement
therapywithidursulfasein
mucopolysaccharidosisII(huntersyndrome).
GenetMed.2006;8(8):465–467.
47.BradleyLA,HaddowHRM,PalomakiGE.
TreatmentofmucopolysaccharidosistypeII
(huntersyndrome):resultsfromasystematic
evidencereview.GenetMed.2017.
48.FedeleAO.Sanfilipposyndrome:causes,
consequences,andtreatments.ApplClinGenet.
2015;8:269–281.
49.GrossDM,WilliamsJC,CaprioliC,Dominquez
B,HowellRR.Echocardiographicabnormalities
inthemucopolysaccharidestoragediseases.Am
JCardiol.1988;61(1):170–176.
50.MuenzerJ,BeekmanRH,ProferaLM,BoveEL.
Severemitralinsufficiencyin
mucopolysaccharidosistypeIII-B(sanfilippo
syndrome).PediatrCardiol.1993;14(2):130–
132.
51.DiNataleP,DiDomenicoC,GarqiuloN,etal.
Treatmentofthemousemodelof


mucopolysaccharidosistypeIIIBwithlentiviralNAGLUvector.BiochemJ.2005;388(Pt
2):639–646.

52.JohnRM,HunterD,SwantanRH.
EchocardiographicabnormalitiesintypeIV
mucopolysaccharidosis.ArchDisChild.
1990;65:746–749.
53.KampmannC,Abu-TairT,GökceS,etal.PLoS
ONE.2016;11(9)[e0162612].
54.TomatsuS,GutierrezM,NishiokaT,etal.
DevelopmentofMPSIVAmouse
(Galnstm(hC79S.mC76S)slu)toleranttohuman
N-acetylgalactosamine-6-sulfatesulfatase.Hum
MolGenet.2005;14(22):3321–3335.
55.HayflickS,RoweS,Kavanaugh-McHughA,
OlsonJL,ValleD.Acuteinfantile
cardiomyopathyasapresentingfeatureof
mucopolysaccharidosisVI.JPediatr.
1992;120:269–272.
56.MarwickTH,BastianB,HughesCF,BaileyBP.
MitralstenosisintheMaroteaux–lamy
syndrome:atreatablecauseofdyspnoea.
PostgradMedJ.1992;68:287–288.
57.OuditGY,ButanyJ,WilliamsWG,ClarkeJT,
IwanochkoRM.Imagesincardiovascular
medicine.Leftventricularaneurysmassociated
withmucopolysaccharidosistypeVIsyndrome


(maroteaux-lamysyndrome).Circulation.
2007;115(5):e60–e62.
58.LakhotiaS,SharmaA,ShrivastavaGP,JainSK.
Maroteaux-lamysyndrome.IndianJPediatr.

2004;71(10):933–935.
59.KampmannC,LampeC,Whybra-TrümplerC,et
al.Cardiacinvolvementandtheimpactof
enzymereplacementtherapy.JInheritMetab
Dis.2014;37(2):269–276.
60.BraunlinE,RosenfeldH,KampmannC,etal.
Enzymereplacementtherapyfor
mucopolysaccharidosisVI:long-termcardiac
effectsofgalsulfase(Naglazyme®)therapy.J
InheritMetabDis.2013;36(2):385–394.
61.MohanUR,HayAA,ClearyMA,WraithJE,
PatelRG.2002cardiovascularchangesin
childrenwithmucopolysaccharidedisorders.
ActaPaediatr.2002;91:799–804.
62.DangelJH.Cardiovascularchangesinchildren
withmucopolysaccharidestoragediseasesand
relateddisorders:clinicalandechocardiographic
findingsin64patients.EurJPediatr.
1998;157:534–538.
63.GniadekTJ,SingerN,BarkerNJ,etal.
Cardiovascularpathologiesin
mucopolysaccharidosistypeVII(slysyndrome).
CardiovascPathol.2015;24(5):322–326.